VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Tom Isaacs president of The Cure Parkinson’s Trust has died
"We're devastated but are focusing on his incredible achievements"
7 hours ago
Sniff test could detect Parkinson’s disease up to a decade earlier
A study has found that white adults with a poor sense of smell are almost five times more likely to develop Parkinson’s disease than those with a stronger smell sense. The research, published in the medical journal ‘Neurology’, found that there was not a statistically significant link between Parkinson’s and smell for black adults. Speculating on the reaction that people from different racial backgrounds had to the test, researchers said: “One possibility is that, compared to white participants, the etiology of olfactory dysfunction in black participants is more diverse and complex, and that Parkinson’s disease-related pathology is a relatively minor contributor.” The team emphasised that the findings should be interpreted with caution – and that further studies are needed before the smell tests can reach a clinical stage.
Spiral drawing test could detect early signs of Parkinson’s
Researchers from RMIT University, Australia, have developed a test that may be able to detect early Parkinson’s – before physical symptoms appear. During the test, participants draw a spiral using a tablet device, and computer software then measures their drawing speed and pen pressure to diagnose the condition. PhD researcher Poonam Zham led the study, published in ‘Frontiers of Neurology’, with the RMIT biomedical engineering research team. Working with Dandenong Neurology, the study involved 62 people diagnosed with Parkinson’s. Half had no visible symptoms and half ranged from mildly- to severely-affected. Professor Dinesh Kumar, chief investigator, said: “The customised software we’ve developed records how a person draws a spiral and analyses the data in real time. “With this tool we can tell whether someone has Parkinson’s disease and calculate the severity of their condition, with a 93% accuracy rate.” Image credit: RMIT University – Professor Dinesh Kumar and Poonam Zham
Asthma drug could halve chance of developing Parkinson’s
A recent study has found that a drug most commonly used for asthma may cut the chances of developing Parkinson’s. The research, carried out by Harvard Medical School, Massachusetts, US, found that those who inhaled salbutamol – a drug found in inhalers – were half as likely to develop the condition. In Parkinson’s disease, a protein named a-synuclein accumulates in various brain cells and can be fatal. To counter this, the research team grew human nerve cells and tested over 1000 medications, finding results to suggest salbutamol could cut the production of a-synuclein. Neurologist Anthony Lang, who works at the University of Toronto, Canada, said the results were “fascinating” and “had come out of the blue”. Despite some encouraging developments, Clemens Scherzer, who was a part of the research team, said clinical trials were “a few years off”.